Journal of Pharmaceutical Research and Technology
Journal homepage: https://journalprt.com/
Open Access

Review Article

Advanced Approaches for Solubility Enhancement of Poorly Water-Soluble Drugs: Techniques, Mechanisms, and Applications

Varsha Soni, Yogesh Sharma, Shivraj Jadhav, Sunil Mahajan, Rushikesh Bachhav, Deepak Sonawane.
Divine Collage of Pharmacy, Satana.

Article Info

Corresponding author: *Varsha Soni,*
varshasoni1507@gmail.com

Received: 15/12/2024
Revised: 23/01/2025
Published: 26/01/2025

Keywords:
Poorly water-soluble drugs, solubility enhancement, nanotechnology, lipid-based systems, bioavailability, amorphous solid dispersions, supercritical fluids.

ABSTRACT:
A major difficulty in medication formulation is the limitation of drug bioavailability and therapeutic efficacy caused by poor water solubility. Numerous conventional and cutting-edge solubility improvement methods have been developed in response to this. Drug solubility has been increased via conventional methods including micronization and salt production, which change the drug's characteristic and reduce particle size. Innovative methods to improve drug absorption and distribution include ionic liquids, nanotechnology, lipid-based systems, and supercritical fluid technology. Drug-excipient interactions, amorphous drug states, and particle size reduction are important factors that underpin these techniques. Notwithstanding their potential, formulation stability and scalability issues still exist, necessitating continued study to make these methods more widely applicable. Future developments point to an increase in interest in integrating several strategies to improve solubility in addition to advancements in drug delivery methods. The study provides a thorough overview of current and new tactics in this field and highlights the significance of enhancing solubility to boost therapeutic efficacy.

INTRODUCTION:

One of the most important obstacles facing medication development is inadequate water solubility. Affecting about 40% of newly discovered chemical entities (NCEs) and up to 90% of compounds in the early phases of drug development pipelines, this problem is ubiquitous. The bioavailability, therapeutic efficacy, and general success as a treatment of a medicine depend much on its solubility. Drugs that show poor solubility find it difficult to dissolve sufficiently in body fluids, which reduces absorption in the gastrointestinal tract and hence restricts their efficacy. For oral medication formulations, which depend on breakdown in gastrointestinal fluids to enable absorption into the bloodstream, this challenge is more acute.

Solubility is intimately related to bioavailability, which is the percentage of an administered medicine that reaches systemic circulation in an active state. As the Noyes-Whitney equation connects the rate of dissolution to surface area, diffusion coefficient, and the concentration gradient across the boundary layer, it describes for many medications the rate-limiting stage in their absorption process. Particularly difficult to make are poorly soluble medications, sometimes categorized under the Biopharmaceutical Classification System (BCS) as Class II (poorly soluble but highly

permeable) or Class IV (poorly soluble and poorly permeable). In these situations, inadequate dissolution rates may prevent even medicines with acceptable pharmacokinetics and pharmacodynamics from reaching therapeutic concentrations in the bloodstream.

Negative solubility has far-reaching consequences. Beyond its effects on bioavailability, low solubility can result in erratic absorption profiles, increased variability in patient response, and the necessity of either higher or more frequent doses, which can cause side effects and lower patient compliance. Furthermore, poor solubility medications show inconsistent in vivo behaviour, which makes it challenging to develop dependable dosages. Even with their possible pharmacological advantages, these restrictions greatly raise the possibility of drug candidates failing during development.

Different conventional and sophisticated methods have been created to handle the solubility issues in medication development. Extensive use of conventional techniques including salt generation and particle size reduction (micronization and nanosizing) has helped to raise surface area and enhance medication dissolving rates. Although these techniques can be useful for some molecules, they usually fail when addressing highly hydrophobic medicines or those showing chemical instability. For instance, micronizing can cause problems with particle aggregation or stability; salt production is limited to ionizable chemicals.

More advanced technologies attempting to surpass the constraints of conventional approaches have surfaced over the past few decades. Among these creative ideas are solid dispersions, lipid-based drug delivery methods, nanotechnology-based techniques, and cyclodextrins. For example, nanotechnology drastically increases surface area and dissolving rates by reducing medication particles to the nanoscale, therefore enhancing the pharmacokinetic profile of many hydrophobic pharmaceuticals. By generating micro- and nano-scale emulsions in the gastrointestinal tract, lipid-based formulations—such as liposomes and self-emulating drug delivery systems (SEDDS—which improve the solubility and bioavailability of lipophilic drugs)—have become somewhat well-known. Furthermore, the invention of amorphous solid dispersions has let formulators provide poorly soluble pharmaceuticals in an amorphous, high-energy state that dissolves more quickly than their crystalline equivalents.

The processes via which these methods improve solubility are several and usually complimentary. While the change of crystalline pharmaceuticals into amorphous forms lowers the energy needed for breakdown, particle size reduction improves the surface area accessible for disintegration. By means of excipients such surfactants and polymers, drug molecules in a dissolved state are stabilized and their tendency to precipitate back into an insoluble form is inhibited. By including poorly soluble pharmaceuticals into lipid droplets, more readily absorbed in the gastrointestinal tract, lipid-based methods improve medication solubilization. Cyclodextrins improve solubility by forming inclusion complexes with drug molecules, therefore protecting them from the aqueous surroundings.

Still, some difficulties exist even with the developments in solubility enhancing methods. Especially for amorphous pharmaceuticals and nanosized particles, formulation stability is a major issue since these forms are generally thermodynamally unstable and prone to recrystallization or aggregation over time. Furthermore, difficult and expensive is scaling up sophisticated technologies as nanotechnology and supercritical fluid procedures from laboratory to industrial manufacture. The choice of approach must also take into account the physicochemical characteristics of the drug, the route of

administration, and the intended therapeutic application, therefore demanding a careful balance between solubility increase and general formulation stability.

We give in this paper a thorough summary of conventional and innovative solubility improvement methods. We will go over the fundamental ideas behind every method, their pragmatic uses in drug development, and the related difficulties with formulation stability and scale-ability. We hope to give researchers and formulators trying to increase the solubility and bioavailability of poorly water-soluble medications a direction by consolidating the present body of knowledge on this issue (1,2).

2. Traditional Solubility Enhancement Techniques

2.1 Particle Reducing Agent Size

Reducing the particle size of the medicine to improve surface area and hence raise the dissolving rate is one of the most often used techniques. Two often utilized methods are micronization—that is, size reduction to the micron scale—and nanosizing—that is, particles with a nanometre scale. Particularly for BCS (Biopharmaceutical Classification System) Class II medications, Patil et al. (2014) claims that nanosizing boosts both surface area and saturation solubility, hence greatly improving dissolution rate.

2.2 Salt Formation

One old approach to improve medication solubility has been salt synthesis. This entails turning the medication into a salt form to increase its ionizing capacity in aqueous solutions. This approach has restrictions for medications that cannot create stable salts even if it is easy and reasonably priced.

2.3 Cooperation Solvency

Co-solvency is the method of increasing the solubility of hydrophobic pharmaceuticals by use of a combination of water and water-miscible organic solvents (Khadka et al., 2014). Common solvents that lower water's polarity and help drugs dissolve include ethanol, propylene glycol, and polyethylene glycol.

2.4 Surfactants

Surfactants reduce interfacial tension between drug particles and the solvent, hence raising solubility. Oral and injectable formulations commonly call for non-ionic surfactants including polysorbates and polyoxyethylene derivatives.

2.5 Solid Distribution

Another typical method where pharmaceuticals are distributed in an inert carrier matrix, such polymers, to increase solubility and bioavailability is solid dispersion. Particularly good at preserving a supersaturated state of the drug in solution are amorphous solid dispersions (ASDs) (3).

3. Techniques of Advanced Solubility Enhancement.

3.1 Methodologies in Nanotechnology

One developing approach for improving drug solubility and bioavailability is nanotechnology. Reduction of particle size to the nanoscale using nanoparticles and nanocrystals greatly increases dissolving rate. Particularly nanocrystals provide benefits by raising pharmacokinetics and enhancing saturation solubility.

3.2 Lipid-Based Formulations

Designed to increase the solubility of lipophilic medicines, lipid-based drug delivery systems include liposomes, nano emulsions, and self-emulsiating drug delivery systems (SEDDS). When SEDDS formulations come into touch with gastrointestinal fluids, they emulsify into fine oil droplets that improve drug absorption.

3.3 Use of Cyclodextrins

Are cyclic oligosaccharides that form inclusion complexes with drug molecules, therefore boosting their solubility by raising exposure to the aqueous environment. Several hydrophobic medications including itraconazole and diclofenac have been effectively formulated using cyclodextrin complexes.

3.4 Amorphous Solid Differsion

Because they lack a crystalline structure, amorphous versions of medicines have greater solubility than their crystalline counterparts. Stable amorphous solid dispersions maintained in their supersaturated condition are produced using advanced processes including hot melt extrusion (HME), therefore preventing recrystallization (4).

3.5 Supercritical fluid technologies

One such approach for increasing solubility is supercritical fluid technology especially supercritical CO_2. Under high pressure, supercritical CO_2 serves as a solvent that can efficiently lower the particle size of poorly soluble medicines, therefore promoting better solubility.

3.6 Ionic Liquids

By upsetting their crystalline structure, ionic liquids salts in liquid form can dissolve poorly soluble medicines. Especially for medications with complicated molecular structures, this developing technology has considerable potential to improve solubility (5).

4. Solubility Enhancement Mechanisms

Several basic mechanisms that increase the rate of dissolution and bioavailability of poorly soluble medicines are the foundation of effective solubility enhancement techniques. These strategies mostly involve adjusting the medication substance's physicochemical characteristics or modifying how it interacts with the dissolving liquid through the use of additives. This section explores current developments in drug-excipient interactions, the shift to amorphous forms, and particle size reduction as we go further into these important mechanisms.

4.1 Diminished Particle Size and Enhanced Surface Area

Reducing particle size is still one of the simplest and most tried-and-true methods for improving medication solubility. The Noyes-Whitney equation provides a good explanation of the relationship between particle size and dissolution rate. It indicates that decreasing particle size increases the surface area accessible for dissolution, which accelerates the rate of dissolution. A drug particle's surface area affects how well it interacts with the solvent, which speeds up the dissolution process. For medications categorized as Biopharmaceutical Classification System (BCS) Class II, which is distinguished by low solubility but high permeability, this strategy is very crucial (6).

Novel Strategies for Reducing Particle Size

Although traditional techniques such as micronization have been used for a long time to reduce particle size, more recent developments in nanotechnology have made it possible to precisely control the process. Innovative methods of reducing particle size include the use of nanoparticles and nanocrystals. Particularly, nanocrystals provide a number of benefits by decreasing the size of the particle to the manometer range, which greatly increases the surface area and saturation solubility. Drug bioavailability and solubility rates are thereby markedly enhanced.

Pure drug particles that have been shrunk to a manometer size typically less than 1,000 nm are known as nanocrystals. Their surface area is greater than that of micronized particles, which leads to a quicker rate of dissolution and enhanced bioavailability. Certain medications, such as paclitaxel and fenofibrate, have been effectively formulated using nanocrystals despite their low water solubility. Wet-milling methods and high-pressure homogenization are two recent, industrially applicable advances in nanocrystal manufacturing (7).

Colloidal dispersions of medication particles stabilized by polymers or surfactants are known as nanosuspensions. The key benefit of nanosuspensions is their capacity to preserve the medication in its nanocrystalline state, which improves stability and inhibits agglomeration. When used in intravenous and oral delivery systems, nanosuspensions are very helpful since they dissolve and absorb quickly after

administration. They also offer flexibility in dosing and storage due to their ability to be lyophilized and reconstituted (8).

Utilizing supercritical fluid technology in particular, supercritical carbon dioxide (CO_2) for particle size reduction is another cutting-edge strategy. Better control over particle morphology is possible with this approach since it enables the creation of ultrafine particles with narrow size distributions. Drug particle engineering can be done solvent-free with supercritical fluids, avoiding the problems that come with using organic solvents and providing a greener option (9). For medications that are heat-sensitive or prone to degrading during traditional micronization procedures, this approach is especially helpful.

All things considered, developments in particle size reduction have produced novel formulation possibilities that greatly improve solubility, particularly for medications with restricted water solubility and those that must function quickly in the body.

4.2 Crystalline vs Amorphous States

A drug's most thermodynamically stable state is usually represented by its crystalline structure, although this stability frequently comes at the expense of low solubility. Amorphous drug forms, on the other hand, are substantially more soluble but thermodynamically less stable due to their lack of an ordered molecular organization. This is because amorphous drugs dissolve more easily in aqueous solutions since they take less energy to dissolve than their crystalline counterparts. For medications that are poorly soluble in water, amorphous forms can attain higher apparent solubility and frequently show faster dissolving rates (10).

Novelties in Non-linear Formulation: Because amorphous pharmaceuticals are inherently unstable, stabilizing them and preventing their recrystallization is a common challenge that has seen tremendous success in recent years.

Amorphous Solid Dispersions (ASDs): Amorphous solid dispersions, in which the medication is disseminated inside a polymeric carrier matrix, are one of the most efficient ways to stabilize amorphous medicines. The drug's amorphous form is stabilized by the polymer, which also inhibits recrystallization and increases the drug's solubility by encouraging a supersaturated condition in solution. Usually, techniques like spray drying and hot melt extrusion (HME) are used to create ASDs. High-energy amorphous medications, which maintain their non-crystalline state during dissolution, can be produced using these methods.

The introduction of new polymers, such as polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), and polyvinyl alcohol (PVA), which offer increased miscibility and stability for a broad range of medications, is one of the most recent advances in ASD technology. Additionally, improvements in computational modeling are assisting scientists in anticipating the most effective polymer-drug pairings, enhancing the stability and effectiveness of ASDs (11).

Molecularly Engineered Amorphous Systems: In an effort to improve the solubility of amorphous medications, several researchers are concentrating on molecular engineering. These systems further lower the energy barrier for dissolving by utilizing molecular interactions between the medication and excipients. For instance, specific ionic or covalent interactions can be utilized to fine-tune the dissolving properties, while hydrogen bonding between drug molecules and excipients can stabilize the amorphous state (12).

Co-Amorphous Systems: Increasingly, co-amorphous systems a combination of two or more active pharmaceutical ingredients (APIs) that creates an amorphous mixture are being used as creative means of improving solubility. Researchers can improve the solubility of both medications and avoid recrystallization by using molecularly compatible APIs. Additionally, this strategy makes it possible to provide several

therapeutic drugs at once, which could enhance therapy results (13).

4.3 Drug Interactions with Excipients

In order to improve solubility, excipient selection is essential. Excipients are inert ingredients in medication formulations, yet their impact on regulating solubility and bioavailability is significant. To increase solubility, excipients can interact with drug molecules in a number of ways, such as reducing the surface tension between the drug and the solvent, keeping the drug dissolved, and avoiding precipitation. In complicated formulations like solid dispersions and lipid-based delivery systems, these interactions are especially crucial.

Creative Applications of Excipients to Improve Solubility

Surfactants: Amphiphilic chemicals known as surfactants improve the wettability of hydrophobic medication particles by lowering surface tension. Surfactants facilitate faster dissolution by improving the interface between the drug particles and the solvent by reducing the interfacial tension between the particles and the dissolving medium. To enhance the solubilization of lipophilic medicines, novel surfactants are being added to medication formulations, such as d-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS) [8]. For instance, it has been demonstrated that TPGS increases the water solubility and bioavailability of medications by creating micelles that can encapsulate hydrophobic medicines. One such medication is paclitaxel (14).

Polymers: Polymers are essential for preserving poorly soluble medications. Examples of these are polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), and enraged. Polymers have the ability to prevent amorphous medications from recrystallizing and sustain supersaturated solutions for extended periods of time. One of the more recent innovations is the use of smart polymers, which release the medicine under controlled conditions in response to environmental cues like pH and temperature. By creating temporary compounds with the medication, these polymers can further improve solubility by avoiding precipitation and enabling prolonged release throughout the body (15).

Cyclodextrins are cyclic oligosaccharides that bind to hydrophobic medicines to create inclusion complexes that effectively solubilize the pharmaceuticals in aqueous conditions. The capacity of cyclodextrins to increase the solubility, stability, and bioavailability of weakly water-soluble medications has led to their increased popularity. Better at soluble in water, modified cyclodextrins such hydroxypropyl-β-cyclodextrin (HP-β-CD) have been effectively incorporated into medication formulations such as dexamethasone and itraconazole.

5. Applications in Drug Development and Commercial Products

The utilization of solubility enhancement techniques has been significant in enhancing the therapeutic efficacy and bioavailability of numerous commercial medications. For example, fenofibrate and sirolimus are two medications that have effectively used nanocrystal technology to increase their rates of absorption and disintegration. Lipid-based formulations, like the one used in cyclosporine, have made it easier for medications that are extremely lipophilic to dissolve. Cyclodextrin complexes, such as those found in meloxicam and itraconazole, have also improved the solubility and bioavailability of medications that would otherwise be poorly soluble in water. These cutting-edge methods facilitate the reformulation of currently available medications as well as the development of novel drug candidates. This leads to enhanced therapeutic efficacy, fewer dosage adjustments, and increased patient compliance—all of which are

essential for the long-term effectiveness of treatment (16).

6. Difficulties and Prospects

6.1 Stability Concerns

Preserving the stability of medication formulations is a major difficulty in solubility enhancement. Drugs in amorphous form can significantly boost solubility, but over time, they are prone to recrystallization due to their inherent instability. The drug's ability to treat a patient may be compromised if this recrystallization results in a return to a less soluble, crystalline state. Stabilization strategies, such as the use of surfactants that lower surface tension and stop aggregation or the addition of polymers that can create protective matrices around the medication, are used to solve this problem.

6.2 Manufacturing and Scalability Issues

There are particular industrial problems when it comes to scaling up the production of innovative formulations, like those that use supercritical fluid techniques or nanotechnology. These techniques can greatly raise production costs and complicate the manufacturing process since they frequently call for specialist equipment and strict attention to quality control measures. For the pharmaceutical sector, ensuring reproducibility and consistency on a greater scale continues to be a major challenge (17).

6.3 Upcoming Patterns

In the upcoming years, a number of trends in solubility enhancement are expected to emerge. These include the creation of increasingly complex medication delivery systems based on nanotechnology and personalized medicine techniques that customize formulations to match the needs of specific patients. Future treatments that are more successful will be made possible by advancements in material science, namely the identification of novel polymers and excipients that will improve the stabilization of supersaturated drug solutions (18).

CONCLUSION:

Enhancing the solubility of poorly water-soluble drugs is paramount for optimizing their bioavailability and therapeutic efficacy. While traditional methods, such as particle size reduction and salt formation, have laid the groundwork for addressing solubility challenges, the advent of advanced techniques—such as nanotechnology, lipid-based formulations, and supercritical fluid technology—has significantly transformed the landscape of drug formulation. Despite the persistent challenges related to stability and scalability, ongoing research and innovation in this field hold great promise for further advancing solubility enhancement strategies. These developments are not only poised to improve drug performance but also to enhance patient outcomes, ultimately contributing to more effective therapies and better healthcare solutions. The future of solubility enhancement is bright, with the potential to unlock new therapeutic possibilities and refine existing treatments for diverse medical needs.

REFERENCES:

1. Savjani KT, Gajjar AK, Savjani JK. Drug Solubility: Importance and Enhancement Techniques. ISRN Pharm. 2012.
2. Patil MP, Patil MS. Nanosuspension: a novel drug delivery system. Int J Pharm Sci Res. 2014.

3. Stahl PH, Wermuth CG. Handbook of Pharmaceutical Salts: Properties, Selection, and Use. Wiley-VCH, 2011.
4. Khadka P, Ro J, Kim H, et al. pharmaceutical particle technologies: An approach to improve drug solubility, dissolution, and bioavailability. Asian J Pharm Sci. 2014.
5. Law D, Schmitt EA, Marsh KC, et al. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations. J Pharm Sci. 2014.
6. Baghel S, Cathcart H, O'Reilly NJ. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, and Formulation Strategies. Pharmaceutics. 2016.
7. Kumar V, Katare OP. Self-emulsifying drug delivery systems: future aspects. Int J Pharm Sci Res. 2005.
8. Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur J Pharm Sci. 2000.
9. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: Basic science and product development. J Pharm Pharmacol. 2012.
10. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poorly water-soluble drugs. Drug Discov Today. 2016.
11. Reverchon E, Adami R. Nanomaterials and supercritical fluids. J Supercrit Fluids. 2006.
12. Moniruzzaman M, Goto M. Ionic liquids: Future solvents and reagents for pharmaceuticals. J Chem Eng Data. 2011.
13. Noyes AA, Whitney WR. The Rate of Solution of Solid Substances in Their Own Solutions. J Am Chem Soc. 1897.
14. Hancock BC, Zografi G. Characteristics and Significance of the Amorphous State in Pharmaceutical Systems. J Pharm Sci. 1997.
15. Dressman JB, Reppas C. In vitro–in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci. 2000.
16. Müller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs–a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol. 2011.
17. Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm. 2007.
18. Bhugra C, Pikal MJ. Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. J Pharm Sci. 2008.
19. Rogers TL, Johnston KP, Williams RO. Solution-based particle formation of pharmaceutical powders by supercritical

or compressed fluid CO_2 and cryogenic spray-freezing technologies. Drug Dev Ind Pharm. 2001.

20. Vasconcelos T, Marques S, das Neves J, Sarmento B. Amorphous solid dispersions: Rational selection of a manufacturing process. Adv Drug Deliv Rev. 2016.